Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen

Wu, Kai; Li, Hong Tao; Qiao, Tai Dong; Li, Cai Ning; Ji, Wan Sheng; Tian, Feng; Wang, Xin; Wang, Biao Luo; Miao, Ji Yan; Ding, Jie; Fan, Dai Ming

doi:10.1111/j.1443-9573.2004.00148.x

Cited by 13 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also found that levels of S-G-17prand and S-PGI were significantly lowered in patients with antral and corpus atrophy than those with NAG; furthermore, their levels decreased with increasing grades of atrophy respectively. These findings were in agreement with previous studies [10,11,13,18,20,21,24] . In the study of Bodger et al [24] of 69 dyspeptic patients 41.20% had Hp-antral atrophy, 52.9% with MAG and 5.9% had corpus atrophy in the Hp positive group.…”

Section: Discussionsupporting

confidence: 83%

“…The serological testing of the gastric mucosa is of importance, given the fact that Hp eradication may cure gastritis and help to prevent further progression of gland loss that might also reduce the risk for gastric cancer [13,18,19,30,41,42] . The panel is a good tool for non-endoscopic diagnosis and screening of atrophic gastritis [10,13,18,20] . The first two authors [10,13] found that 82 and 96% respectively of their dyspeptic patients went into same 'gastritis categories' with both the S-G-17prand and S-PGI and the endoscopy/histopathology by using the algorithm.…”

Section: Discussionmentioning

confidence: 99%

“…The sample for postprand amidated gastrin-17 (G-17prand) was taken 20 minutes after a protein drink (10 g chocolate flavored soy protein powder foil bag dissolved in 100ml water, Biohit Plc, Helsinki, Finland). Due to the sensitivity of S-G-17 (easily destroyed), it is recommended that coagulation of tubes for serum must not exceed 30 min at room temperature (20)(21)(22)(23)(24)(25) o C). Otherwise, at warmer temperatures the blood tubes for serum are placed into crushed ice bath for coagulation that should not exceed 60 min.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

The Serological Gastric Biopsy: A Non-endoscopical/Histopathologic Diagnostic Approach in Management of the Dyspeptic Patients

Mahmoud¹,

H²,

Hegazi³

et al. 2006

American J. of Immunology

View full text Add to dashboard Cite

Objective of this study was to asses the sensitivity, specificity and the predictive value of a 'gastropanel' blood test, including serum pepsinogen I (S-PGI) and amidated gastrin-17 (S-G-17) in the diagnosis of atrophic gastritis most probably due to helicobacter pylori (Hp) and to compare the results of serology with the endoscopic/histopathologic findings as a gold standard diagnostic tool. This study comprised 86 dyspeptic outpatients who underwent a diagnostic gastroscopy with multiple biopsies from the antrum and corpus for histopathologic examination. Histopathologically, the series of cases included 46 patients diagnosed as having atrophic gastritis. Twenty five had an antral atrophy, 6 had corpus atrophy and 15 patients had an atrophic gastritis in both the antrum and corpus (multifocal atrophic gastritis) MAG. The remaining 40 cases were considered as controls, 32 had a non-atrophic gastritis (NAG) and both the antrum and corpus were normal and healthy in 8 subjects. The fasting levels of S-PGI and antibodies to Hp IgG-antibodies (S-HpAb) and postprandial amidated S-G-17 (S-G-17prand) were measured 20 min after a protein-rich drink and were determined using enzyme immunoassay (EIA) methods. The serologic and morphologic results were compared with estimating the sensitivity, specificity, positive and negative predictive (PPV and NPV) and accuracy values of the tests (S-G-17 and S-PGI). Mean values of both S-G-17prand and S-PGI decreased with increasing grade of antral and corpus atrophy, respectively. A low S-PGI (<25 µg L^-1) was found in 4 of 6 patients with corpus atrophy (66.70%) and in 5 of 32 (15.62%) patients with NAG in the biopsy specimens. A low S-G-17prand (<5 pmol L^-1) was found in 13 patients with Hp-associated antral atrophy and in 5 of 32 (15.62%) patients with NAG. The diagnosis of gastritis obtained with the blood test panel is in good agreement with the endoscopic and biopsy findings: 92% of the patients went into same gastritis categories with both the panel and endoscopic/histopathologic findings. The sensitivity, specificity, PPV, NPV and accuracy values of the blood test panel (S-G-17prand and S-PGI) in delineation of patients with atrophic gastritis (either in the antrum or the corpus, or both) versus NAG and normal stomach were 87.5, 82.60, 81.40, 88.40 and 85% respectively. Low levels of S-G-17prand and S-PGI are conceivable biomarkers of atrophic gastritis. The serologic method gave a reasonable sensitivity, specificity, PPV, NPV and accuracy values in the diagnosis of atrophic gastritis. So, it may be offered as the screening tool for atrophic gastritis

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The Serological Gastric Biopsy: A Non-endoscopical/Histopathologic Diagnostic Approach in Management of the Dyspeptic Patients

Mahmoud¹,

H²,

Hegazi³

et al. 2006

American J. of Immunology

View full text Add to dashboard Cite

show abstract

“…When the study outcome was the extent of atrophy of the gastric corpus, values ranged between sensitivities of 9.4% to 92.3% and specificities of 9.9% to 100% [102][103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118][119][120], but other methods of reporting results found statistically significantly lower mean values of serum pepsinogen in extensive atrophic gastritis [106,111,[121][122][123][124], significant correlations between atrophy extent and serum pepsinogen values [102,125,126], or significant odds/likelihood ratios for progression of atrophy to the corpus [113,127,128].…”

Section: Biopsy Samplingmentioning

confidence: 99%

Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

et al. 2011

View full text Add to dashboard Cite

Atrophic gastritis, intestinal metaplasia, and epithelial dysplasia of the stomach are common and are associated with an increased risk for gastric cancer. In the absence of guidelines, there is wide disparity in the management of patients with these premalignant conditions. The European Society of Gastrointestinal Endoscopy, the European Helicobacter Study Group, the European Society of Pathology, and the Sociedade Portuguesa de Endoscopia Digestiva have therefore combined efforts to develop evidence-based guidelines on the management of patients with precancerous conditions and lesions of the stomach. A multidisciplinary group of 63 experts from 24 countries developed these recommendations by means of repeat online voting and a meeting in June 2011 in Porto, Portugal. The recommendations emphasize the increased cancer risk in patients with gastric atrophy and metaplasia and the need for adequate staging in the case of high-grade dysplasia, and they focus on treatment and surveillance indications and methods.

show abstract

“…The PG I/II ratio is therefore decreased. Measuring PG helps to assess the extent of the atrophy . Patients with atrophy at the gastric body have reduced levels of PG I and a lower PG I/II ratio but increased serum gastrin‐17 levels.…”

Section: Outcomes Of Chronic Gastritis and The Prevention Of Gastric mentioning

confidence: 99%

Chinese consensus on chronic gastritis (2017, Shanghai)

Fang¹,

Du²,

Liu³

et al. 2018

J of Digest Diseases

View full text Add to dashboard Cite

Diagnosis of atrophic body gastritis in Chinese patients by measuring serum pepsinogen

Abstract: The serum PGI:PGII ratio appears to be a sensitive and specific assay for corpus atrophy, thus providing a noninvasive and indicative test for diagnosis of atrophic gastritis.

Cited by 13 publications

References 18 publications

The Serological Gastric Biopsy: A Non-endoscopical/Histopathologic Diagnostic Approach in Management of the Dyspeptic Patients

The Serological Gastric Biopsy: A Non-endoscopical/Histopathologic Diagnostic Approach in Management of the Dyspeptic Patients

Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

Chinese consensus on chronic gastritis (2017, Shanghai)

Contact Info

Product

Resources

About